Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
AK105 and anlotinib
The First People's Hospital of Lianyungang
Cervical Cancer
1 trial -
Anlotinib
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Effect of Drugs
1 trial -
Anlotinib and Sintilimab injection
The First People's Hospital of Lianyungang
Advanced Hepatocellular Carcinoma
1 trial -
Anlotinib combined Docetaxel
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Anlotinib+ Liposomal Doxorubicin
The First People's Hospital of Lianyungang
Sarcoma
1 trial -
Experimental: tislelizumab+anlotinib
The First People's Hospital of Lianyungang
Thymic Carcinoma
1 trial -
Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
The First People's Hospital of Lianyungang
HER2-Negative Breast Cancer
1 trial -
The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
anlotinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Sarcoma, Soft Tissue
1 trial -
anlotinib
Fudan University
Extensive-stage Small Cell Lung Cancer
1 trial -
anlotinib +TQB2450 + Oxaliplatin+S-1
The First People's Hospital of Lianyungang
Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
1 trial -
anlotinib combined with penpulimab
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
anlotinib+TQB2450+nab-paclitaxel+cisplatin
The First People's Hospital of Lianyungang
Advanced Biliary Tract Cancer
1 trial -
osimertinib mesylate tablets and anlotinib hydrochloride capsules
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial -
Anlotinib hydrochloride,Penpulimab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Realgar-Indigo Naturalis Formulation Combined with Anlotinib
The First People's Hospital of Lianyungang
Platinum-resistant Ovarian Cancer (PROC)
1 trial -
Anlotinib Hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung
1 trial -
Anlotinib hydrochloride
The First People's Hospital of Lianyungang
Non-Small-Cell Lung Cancer
2 trials -
Hydrochloride anlotinib
Zhongnan Hospital
Uterine Cervical Neoplasms
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources